1
|
Thor M, Shepherd AF, Apte A, Gelblum D, Wu AJ, Simone CB, Chaft J, Rimner A, Gomez DR, Deasy JO, Shaverdian N. A Novel FDG PET and Mean Lung Dose Model to Identify Stage III NSCLC Patients at High Risk of Developing Early Radiation Pneumonitis. Int J Radiat Oncol Biol Phys 2023; 117:S169. [PMID: 37784422 DOI: 10.1016/j.ijrobp.2023.06.271] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Early radiation pneumonitis (RPEarly) is a primary reason for the premature discontinuation of durvalumab consolidation and can lead to poor survival in patients with stage III non-small cell lung cancer (NSCLC). Currently, there are no RP risk models specifically tested for RPEarly. Here, we tested the applicability of published RP models for predicting RPEarly and explored the value of integrating pretreatment FDG-PET parameters. MATERIALS/METHODS The cohort consisted of all 178 LA-NSCLC patients treated with concurrent chemoradiation (cCRT) and durvalumab between May 2017 and December 2021. RPEarly was defined as RP occurring within three months of cCRT completion; late RP (RPLate) was defined as any later occurring RP. The three published RP models analyzed included: 1) Mean lung dose (MLD), 2) MLD, age, pulmonary comorbidity, smoking status, and tumor location, and 3) MLD, age and pulmonary comorbidity. In addition, pretreatment FDG PET-CT scans were used to calculate SUV parameters from auto-segmented normal lung contours: 10th- and 90th percentile (SUVP10, SUVP90), maximum, mean (SUVmean), minimum, and standard deviation. The RP models were fit to RPEarly, RPLate, and RPEarly+Late in the 178 patients. To assess the association between FDG PET parameters and RP unbiasedly, the cohort was then randomly split, but enforcing similar RP rates, into a two-thirds derivation and a one-third validation subset. Model performance was assessed by AUC, p-values and the Hosmer-Lemeshow test (pHL; ideally ∼0.50). RESULTS The rates of RPEarly, RPLate, and RPEarly+Late were 12%, 11%, and 23%, respectively (corresponding to 21, 20, and 41 events). Only the MLD model significantly predicted RPEarly (AUC = 0.70; p = 0.04; pHL = 0.84); none of the three models predicted RPLate or RPEarly+Late. Among the FDG PET parameters, SUVP10, SUVP90 and SUVmean predicted RPEarly with similar performance (AUC = 0.69-0.73; p = 0.005-0.01; pHL = 0.68-0.72), and, therefore, bivariate models were built between MLD and each of SUVP10, SUVP90 and SUVmean. Only the MLD + SUVP90 model generalized in the validation subset (AUC = 0.63; p = 0.03; pHL = 0.89) and was thus deemed the final model for RPEarly. A final re-fitting of all model coefficients to the whole cohort indicated improvement over using the published MLD alone model (AUC = 0.75 vs. 0.70; p-value = 0.0006 vs. 0.04; pHL = 0.67 vs. 0.84). Risk of RPEarly is thus estimated as: RPEarly = 1/(1 = e-x); x = -5.79 + (1.57*MLD) + (0.14* SUVP90). CONCLUSION Patients at risk for RPEarly can be accurately identified prior to treatment by combining a re-fitted version of the published Mean Lung Dose model and pre-treatment FDG PET SUVP90 of the normal lung. This refined model can be used to identify patients with an exacerbated risk for premature durvalumab discontinuation due to RPEarly and could allow for interventions and/or the generation of "RPEarly sparing" treatment plans to improve overall treatment outcomes.
Collapse
Affiliation(s)
- M Thor
- Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY
| | - A F Shepherd
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - A Apte
- Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY
| | - D Gelblum
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY
| | - A J Wu
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY
| | | | - J Chaft
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - A Rimner
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY
| | - D R Gomez
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY
| | - J O Deasy
- Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY
| | - N Shaverdian
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY
| |
Collapse
|
2
|
Carbone D, Waqar S, Chaft J, Kris M, Johnson B, Lee J, Wistuba I, Kwiatkowski D, Bunn P, Schulze K, Johnson A, Brandao E, Awad M, Reckamp K, Chiang A, Nicholas A, Rusch V. 145MO Updated survival, efficacy and safety of adjuvant (adj) atezolizumab (atezo) after neoadjuvant (neoadj) atezo in the phase II LCMC3 study. J Thorac Oncol 2023. [DOI: 10.1016/s1556-0864(23)00339-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/04/2023]
|
3
|
Mao S, Rosner S, Forde P, Chaft J, Jones D, Spicer J, Hales R, Ha J, Hu C, Voong R. Patterns of Failure in Resectable Stage I-IIIA NSCLC Treated with Neoadjuvant Immunotherapy Combinations, a Secondary Analysis of a Prospective Trial. Int J Radiat Oncol Biol Phys 2022. [DOI: 10.1016/j.ijrobp.2022.07.1527] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
4
|
Moore Z, Huang X, Lobaugh S, Geyer A, Gelblum D, Shepherd A, Shaverdian N, Wu A, Chaft J, Zauderer M, Rudin C, Chawla M, Jones D, Sopka D, Mak R, Liao Z, Gomez D, Zhang Z, Paik P, Rimner A. Biomarkers Associated with Pulmonary Exacerbations in a Prospective, Placebo-Controlled, Randomized Trial of Nintedanib for the Treatment of Radiation Pneumonitis. Int J Radiat Oncol Biol Phys 2022. [DOI: 10.1016/j.ijrobp.2022.07.2128] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
|
5
|
Tian S, Kozono D, Ohri N, Jolly S, Johnson B, Chaft J, Toloza E, Ding B, Ngiam C, Schulz K, Bara I, Lee J. NAUTIKA1: A Multicenter Phase II Study with a PD-L1+ Cohort of Patients Receiving Atezolizumab (Atezo) with Low-Dose Stereotactic Body Radiation Therapy (SBRT) as Neoadjuvant Therapy for Resectable Stage IB-III NSCLC. Int J Radiat Oncol Biol Phys 2022. [DOI: 10.1016/j.ijrobp.2022.07.1550] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
6
|
Shaverdian N, Shepherd A, Offin M, Gelblum D, Wu A, Simone C, Schoenfeld A, Jones D, Rimner A, Chaft J, Riaz N, Gomez D. Tumor Mutational Burden Predicts Progression-Free Survival and Local-Regional Control in Locally Advanced Non-Small Cell Lung Cancer Patients Treated with Chemoradiation and Durvalumab. Int J Radiat Oncol Biol Phys 2022. [DOI: 10.1016/j.ijrobp.2022.07.1546] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
7
|
Lee J, Sepesi B, Toloza E, Lin J, Pass H, Johnson B, Heymach J, Johnson M, Ding B, Schulze K, Zhu Q, Ngiam C, Brandão E, Bara I, Chaft J. EP02.04-005 Phase II NAUTIKA1 Study of Targeted Therapies in Stage II-III NSCLC: Preliminary Data of Neoadjuvant Alectinib for ALK+ NSCLC. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.390] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
8
|
Oezkan F, Hilz S, Grindheim J, Wallace A, Seweryn M, Reuben A, Zhang J, Owen D, Nicholas A, Yadav M, Nagarkar D, de Almeida P, Ebert P, Osborne E, Johnson A, Lee J, Bunn P, Johnson B, Chaft J, Kris M, Rusch V, Schulze K, Kwiatkowski D, Wistuba I, Carbone D. OA14.06 T-Cell Dynamics in Response to Neoadjuvant Atezolizumab in Early NSCLC by Antigen Response and T-Cell Receptor Sequencing. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.071] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
9
|
Spigel D, Peters S, Ahn MJ, Tsuboi M, Chaft J, Harpole D, Barlesi F, Abbosh C, Mann H, May R, Dennis P, Swanton C. 93TiP MERMAID-2: Phase III study of durvalumab in patients with resected, stage II-III NSCLC who become MRD+ after curative-intent therapy. J Thorac Oncol 2021. [DOI: 10.1016/s1556-0864(21)01935-3] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
10
|
Lee J, Wistuba I, Ngiam C, Yu W, Schulze K, Rocha M, Bara I, Carbone D, Johnson B, Kwiatkowski D, Center M, Chaft J. P03.04 Phase II Study of TKIs as Neo(adjuvant) Therapy in Stage II–III Resectable NSCLC with ALK, ROS1, NTRK or BRAFV600 Alterations. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.377] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
11
|
Lee J, Chaft J, Nicholas A, Patterson A, Waqar S, Toloza E, Haura E, Raz D, Reckamp K, Merritt R, Owen D, Finley D, Mcnamee C, Blasberg J, Garon E, Mitchell J, Doebele R, Baciewicz F, Nagasaka M, Pass H, Schulze K, Phan S, Johnson A, Bunn P, Johnson B, Kris M, Kwiatkowski D, Wistuba I, Carbone D, Rusch V. PS01.05 Surgical and Clinical Outcomes With Neoadjuvant Atezolizumab in Resectable Stage IB–IIIB NSCLC: LCMC3 Trial Primary Analysis. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.320] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
|
12
|
Peters S, Spigel D, Ahn M, Tsuboi M, Chaft J, Harpole D, Goss G, Barlesi F, Abbosh C, Poole L, May R, Dennis P, Swanton C. P03.03 MERMAID-1: A Phase III Study of Adjuvant Durvalumab plus Chemotherapy in Resected NSCLC Patients with MRD+ Post-Surgery. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.376] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
13
|
Carbone D, Lee J, Kris M, Wistuba I, Kwiatkowski D, Owen D, Bunn P, Johnson B, Oezkan F, Tang Y, Parra E, Lozanski G, Rivard C, Schulze K, Nicholas A, Johnson A, Grindheim J, Shames D, Phan S, Toloza E, Haura E, Mcnamee C, Gainor J, Patterson A, Waqar S, Raz D, Reckamp K, Finley D, Rusch V, Chaft J, Abel J. OA06.06 Clinical/Biomarker Data for Neoadjuvant Atezolizumab in Resectable Stage IB-IIIB NSCLC: Primary Analysis in the LCMC3 Study. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.294] [Citation(s) in RCA: 16] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
14
|
Shepherd A, Yu A, Al-Sadawi M, Peleg A, Iocolano M, Leeman J, Imber B, Wild A, Offin M, Chaft J, Huang J, Rimner A, Wu A, Gelblum D, Shaverdian N, Gomez D, Simone Ii C, Yorke E, Jackson A. FP04.01 Heart Dose is a Dosimetric Predictor of Overall Survival in Patients with NSCLC Undergoing Post-Operative Radiation Therapy. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.088] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
15
|
Zhang S, Chaft J, Wu A, Cuaron J, Gelblum D, von Reibnitz D, Gelb E, Ng K, Yorke E, Rimner A. Final Results of a Phase I Trial of Stereotactic Body Radiotherapy for Larger (>3cm) Inoperable Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 2020. [DOI: 10.1016/j.ijrobp.2020.07.1208] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
16
|
Rimner A, Offin M, Shaverdian N, McKnight D, Li H, Mccune M, Patson B, Kotecha R, Gomez D, Chaft J. Durvalumab with Concurrent Definitive Radiation Therapy (DART) for Locally-Advanced Non-Small Cell Lung Cancer - A Phase II Study. Int J Radiat Oncol Biol Phys 2020. [DOI: 10.1016/j.ijrobp.2020.07.584] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
17
|
Zhang J, Ji Z, Caushi J, El Asmar M, Anagnostou V, Cottrell T, Chan H, Guo H, Merghoub T, Chaft J, Wolchok J, Reuss J, Marrone K, Naidoo J, Gabrielson E, Taube J, Brahmer J, Velculescu V, Zhao N, Hellmann M, Forde P, Pardoll D, Yegnasubramanian S, Ji H, Smith K. MA11.10 Peripheral T Cell Repertoire Evolution in Resectable NSCLC Treated with Neoadjuvant PD-1 Blockade. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.590] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
18
|
Oezkan F, He K, Owen D, Pietrzak M, Cho J, Kitzler R, Pearson R, Rusch V, Chaft J, Suh R, Blasberg J, Reckamp K, Raz D, Kneuertz P, Fiorillo L, Garon E, Nicholas A, Johnson A, Schulze K, Grindheim J, Banchereau R, Phan S, Bunn P, Kwiatkowski D, Johnson B, Kris M, Wistuba I, Lee J, Lozanski G, Carbone D. OA13.07 Neoadjuvant Atezolizumab in Resectable NSCLC Patients: Immunophenotyping Results from the Interim Analysis of the Multicenter Trial LCMC3. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.482] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
19
|
Chaft J. PL03.02 Bringing Immunotherapy into the Curative Setting: Emerging Data on Neoadjuvant Strategies. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.063] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
20
|
Shaverdian N, Zhang Z, Lobaugh S, Deasy J, Offin M, Preeshagul I, Hellmann M, Chaft J, Shepherd A, Gelblum D, Lee N, Gomez D, Wu A, Rimner A. Real-World Evaluation of Consolidative Durvalumab in Locally Advanced Non-Small-Cell Lung Cancer Treated with Definitive Chemoradiation. Int J Radiat Oncol Biol Phys 2019. [DOI: 10.1016/j.ijrobp.2019.06.2437] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
21
|
Thor M, Fitzgerald K, Iyer A, Apte A, Oh J, Chaft J, Wu A, Offin M, Gelblum D, Deasy J, Rimner A. Predicting Tumor Progression in Early Stage Non-small Cell Lung Cancer Using Pre-treatment Imaging. Int J Radiat Oncol Biol Phys 2019. [DOI: 10.1016/j.ijrobp.2019.06.1394] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
22
|
Luo L, Samstein R, Dick-Godfrey R, Oro F, Sonnick M, Paik P, Chaft J, Rimner A, Wu A. Genetic Predictors of Response to Chemoradiation in Stage III Non-Small-Cell Lung Cancer. Int J Radiat Oncol Biol Phys 2018. [DOI: 10.1016/j.ijrobp.2018.07.156] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
23
|
El Asmar M, Zhang J, Caushi J, Ji Z, Anagnostou V, Cottrell T, Chan H, Suri P, Guo H, Marrone K, Naidoo J, Merghoub T, Chaft J, Hellmann M, Taube J, Brahmer J, Forde P, Velculescu V, Pardoll D, Ji H, Smith K. MA04.11 Neoantigen Targeting and T Cell Reshaping in Resectable NSCLC Patients Treated with Neoadjuvant PD-1 Blockade. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.348] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
24
|
Rusch V, Chaft J, Johnson B, Wistuba I, Kris M, Lee J, Bunn P, Kwiatkowski D, Reckamp K, Finley D, Haura E, Waqar S, Doebele R, Garon E, Blasberg J, Nicholas A, Schulze K, Phan S, Gandhi M, Carbone D. MA04.09 Neoadjuvant Atezolizumab in Resectable Non-Small Cell Lung Cancer (NSCLC): Updated Results from a Multicenter Study (LCMC3). J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.346] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
25
|
Oxnard G, Mandrekar S, Hillman S, Tan A, Govindan R, Wigle D, Malik S, Watt C, Gerber D, Chaft J, Dahlberg S, Kelly K, Faggen M, Stella P, Tazi K, Gandara D, Ramalingam S, Stinchcombe T. P1.16-47 Adjuvant Targeted Therapy Following Standard Adjuvant Therapy for Resected NSCLC: An Initial Report from ALCHEMIST (Alliance A151216). J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.1016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
26
|
Cheng M, Yang J, Shady M, Ulz P, Heitzer E, Socci N, Seshan V, Offin M, Stephens D, Makhnin A, Tandon N, Datta S, Selcuklu D, Huberman K, Vanness K, Gedvilaite E, Viale A, Arcila M, Ladanyi M, Chaft J, Rudin C, Berger M, Solit D, Li B, Tsui D. OA 10.05 Non-Invasive Molecular Profiling in NSCLC by Targeted and Whole Exome Analysis of Plasma cfDNA. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.385] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
27
|
Shepherd A, Leeman J, Wild A, Imber B, Pei X, Gelb E, Yorke E, Isbell J, Chaft J, Gelblum D, Wu A, Rimner A. A Comparison of Trimodality Therapy Versus Definitive Concurrent Chemoradiation in Patients With Stage IIIA Non–small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 2017. [DOI: 10.1016/j.ijrobp.2017.06.1787] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
28
|
Imber B, Leeman J, Shepherd A, Wild A, Pei X, Gelb E, Chaft J, Mychalczak B, Jones D, Isbell J, Yorke E, Wu A, Rimner A. Prognostic Impact of Tumor Location and Lymph Node Burden for Patients with Stage IIIA Non–small Cell Lung Cancer Receiving Postoperative Radiation Therapy. Int J Radiat Oncol Biol Phys 2017. [DOI: 10.1016/j.ijrobp.2017.06.1714] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
29
|
Wild A, Shepherd A, Leeman J, Imber B, Pei X, Gelblum D, Gelb E, Chaft J, Jones D, Isbell J, Yorke E, Wu A, Rimner A. FDG-PET Maximum Standardized Uptake Value is Prognostic for Survival and Disease-Free Survival in Stage IIIA-N2 Non–small Cell Lung Cancer Patients Who Receive Postoperative Radiation Therapy. Int J Radiat Oncol Biol Phys 2017. [DOI: 10.1016/j.ijrobp.2017.06.1802] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
30
|
Peters S, Carcereny Costa E, Garassino M, Christoph D, Kurata T, Chaft J, Johnson M, Mocci S, Gettinger S, Felip E. Atezolizumab as first-line (1L) therapy for advanced non-small cell lung cancer (NSCLC) in PD-L1–selected patients: Efficacy data from the BIRCH trial. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx091.004] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
31
|
Eberhardt W, Garassino MC, Rizvi NA, Besse B, Jänne PA, Peters S, Keong Toh C, Kurata T, Carcereny Costa E, Koczywas M, Felip Font E, Chaft J, Qiu J, Kowanetz M, Zou W, Coleman S, Mocci S, Sandler A, Gettinger S, Johnson ML. Atezolizumab as first-line therapy (1L) for advanced PD-L1-selected NSCLC patients: updated ORR, PFS, OS and exploratory biomarker results from the BIRCH study. Pneumologie 2017. [DOI: 10.1055/s-0037-1598277] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Affiliation(s)
- W Eberhardt
- Universitätsklinikum Essen, Ruhrlandklinik, West German Cancer Center, Universität Duisburg-Essen
| | - MC Garassino
- Fondazione Irccs Istituto Nazionale Dei Tumori, Thoracic Oncology Unit
| | - NA Rizvi
- New York-Presbyterian/Columbia University Medical Center
| | - B Besse
- Gustave Roussy, Villejuif France and Paris Sud University
| | | | | | | | - T Kurata
- Kansai Medical University Hirakata Hospital
| | - E Carcereny Costa
- Catalan Institute of Oncology Badalona – Germans Trias I Pujol Hospital Badalona
| | | | | | - J Chaft
- Memorial Sloan Kettering Cancer Center
| | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Rizvi N, Balmanoukian A, Goldberg S, Chaft J, Sanborn R, Rebelatto M, Narwal R, Robbins P, Gu Y, Karakunnel J, Antonia S. 418O Phase 1b study of the safety and antitumour activity of durvalumab (MEDI4736) + tremelimumab in advanced NSCLC. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv532.02] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
33
|
Oro F, Sonnick M, Wu A, Shi W, Zhang Z, Gelblum D, Paik P, Yorke E, Rosenzweig K, Chaft J, Rimner A. Identifying the Optimal Radiation Dose in Locally Advanced Non-Small Cell Lung Cancer (NSCLC) Treated With Definitive Radiation Therapy Without Concurrent Chemotherapy. Int J Radiat Oncol Biol Phys 2015. [DOI: 10.1016/j.ijrobp.2015.07.214] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|